Home > Press > 180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018
Abstract:
180 Degree Capital Corp. (NASDAQ:TURN) (“180” and the “Company”), today reported its financial results as of September 30, 2018. Key results for the quarter and year to date include:
Q2 2018 -> Q3 2018 Q4 2017-> Q3 2018
Net Asset Value Per Share (NAV) $2.91 -> $2.81 (-3.4%) $2.60 -> $2.81 (+8.1%)
Stock Price $2.31 -> $2.17 (-6.1%) $1.97 -> $2.17 (+10.2%)
Stock Price / NAV 79.4% -> 77.2% 75.8% -> 77.2%
Cash + Liquid Securities $43.8mm* -> $39.6mm
(-9.6%) $27.7mm -> $39.6mm
(+43.0%)
* Including $7 million proceeds from sale of securities of HZO, Inc., in July 2018
180’s public portfolio decreased by $2.8 million, $0.09 per share, or -8.8%, during the quarter, primarily due to decreases in value of Adesto Technologies Corporation, Mersana Therapeutics, Inc. and Synacor, Inc. That decrease was partially offset by increases in value of Airgain, Inc., TheStreet, Inc., and PDL BioPharma, Inc.
180’s private portfolio increased by $400,000, with increases in value led by AgBiome, LLC and D-Wave Systems, Inc., offset by decreases in value in Produced Water Absorbents, Inc. and Petra Pharma Corporation.
180 sold its securities of HZO, Inc. for $7 million.
180 announced new investments in Lantronix, Inc., and PDL BioPharma, Inc.; as well as the identities of unannounced positions started in Q2 2018: Airgain, Inc., and Emcore Corporation.
The Company also published a letter to shareholders that can be viewed at https://ir.180degreecapital.com/financial-results.
“Following last quarter’s 10% increase in NAV, we had a decline of 3.4% this quarter,” said Kevin M. Rendino, Chief Executive Officer of 180. “Year to date, our public market performance has generated a gross total return of 35.9%. This performance is the primary reason our NAV has risen 8% in 2018.”
Mr. Rendino and Daniel Wolfe, President, Chief Financial Officer and Portfolio Manager, will host a conference call tomorrow, Tuesday, October 30, 2018, at 9am Eastern Time, to discuss the results from the third quarter of 2018. The call can be accessed by phone at (641) 715-0632 passcode 415049 or via the web at join.freeconferencecall.com/180degreecapital. Additionally, slides that will be referred to during the presentation can be found on 180’s investor relations website at https://ir.180degreecapital.com/ir-calendar.
####
About 180 Degree Capital Corp.
180 Degree Capital Corp. is a publicly traded registered closed-end fund focused on investing in and providing value-added assistance through constructive activism to what we believe are substantially undervalued small, publicly traded companies that have potential for significant turnarounds. Our goal is that the result of our constructive activism leads to a reversal in direction for the share price of these investee companies, i.e., a 180-degree turn. Detailed information about 180 and its holdings can be found on its website at www.180degreecapital.com.
Forward-Looking Statements
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's securities filings filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference and link to the website www.180degreecapital.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release. 180 is not responsible for the contents of third-party websites.
For more information, please click here
Contacts:
Press Contact:
Daniel B. Wolfe
180 Degree Capital Corp.
973-746-4500
Copyright © 180 Degree Capital Corp.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||